Search research articles
Contact Us
Filters
Showing results (81-90 of 90) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 90 results.
Minerva Endocrinologica
|
July 1, 1991
Primary hyperparathyroidism. Our experience
L De Marinis, A Mancini, R Sciuto, et al.
Minerva Medica
|
April 1, 1990
[The role of autoimmune mechanisms in the hyperthyroidism-viral hepatitis syndrome: a possible noncausal association. A review of the literature and the authors' own cases]
A Mancini, L De Marinis, C Fiumara, et al.
Minerva Chirurgica
|
June 15, 1981
[Typical, atypical and malignant bronchial carcinoid]
F Sartori, R Binda, F Calabrò, et al.
Minerva Chirurgica
|
June 15, 1981
[Bronchial cylindroma (adenocystic carcinoma)]
F Sartori, R Binda, F Calabrò, et al.
European Urology
|
April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients
S G Williams, R Gandour-Edwards, A D Deitch, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 18, 2001
A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis
A Santo, R Pedersini, F Pasini, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
L Antonuzzo, M Maruzzo, U De Giorgi, et al.
ESMO Open
|
May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G Fornarini, S E Rebuzzi, G L Banna, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 90) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 90 results.
Minerva Endocrinologica
|
July 1, 1991
Primary hyperparathyroidism. Our experience
L De Marinis, A Mancini, R Sciuto, et al.
Minerva Medica
|
April 1, 1990
[The role of autoimmune mechanisms in the hyperthyroidism-viral hepatitis syndrome: a possible noncausal association. A review of the literature and the authors' own cases]
A Mancini, L De Marinis, C Fiumara, et al.
Minerva Chirurgica
|
June 15, 1981
[Typical, atypical and malignant bronchial carcinoid]
F Sartori, R Binda, F Calabrò, et al.
Minerva Chirurgica
|
June 15, 1981
[Bronchial cylindroma (adenocystic carcinoma)]
F Sartori, R Binda, F Calabrò, et al.
European Urology
|
April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients
S G Williams, R Gandour-Edwards, A D Deitch, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 18, 2001
A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis
A Santo, R Pedersini, F Pasini, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
L Antonuzzo, M Maruzzo, U De Giorgi, et al.
ESMO Open
|
May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G Fornarini, S E Rebuzzi, G L Banna, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Page
of 9